The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000802303p
Ethics application status
Help: Ethics application status
Submitted, not yet approved
Date submitted
Help: Date submitted
16/06/2026
Date registered
Help: Date registered
3/07/2026
Date last updated
Help: Date last updated
3/07/2026
Date data sharing statement initially provided
Help: Data sharing statement date
3/07/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
Effectiveness of Innovative Low-dose Radiotherapy for Osteoarthritis Relief (iROAR) and Management: A multicentre clinical registry
Scientific title
iROAR: Effectiveness of Innovative Low-dose Radiotherapy for Osteoarthritis Relief and Management in participants with pre-existing diagnosis of osteoarthritis : A multicentre clinical registry
Additional trial identifiers [1] 317594 0
iROAR
Universal Trial Number (UTN)
Trial acronym
iROAR
Related trial records

Health condition
Health condition(s) studied:
Osteoarthritis 342355 0
Condition category
Condition code
Musculoskeletal 338489 338489 0 0
Osteoarthritis

Intervention/exposure
Study type
Observational
Patient registry
True
Target follow-up duration
24
Target follow-up type
Months
Description of the intervention or exposure
Participants enrolled in the registry will receive low-dose radiotherapy (LDRT) as part of standard clinical care for the management of symptomatic osteoarthritis. LDRT is delivered to the affected joint using either photon or electron radiotherapy techniques, as determined by the treating Radiation Oncologist.
The recommended dosing regimen consists of a total dose of 3 Gy administered in 6 fractions (0.5 Gy per fraction) over approximately 2–3 weeks, typically delivered on alternate days.
Treatment is planned and delivered according to institutional radiotherapy protocols, with the treatment field encompassing the painful joint and adjacent periarticular structures.
Participants may receive one additional course of LDRT (retreatment) to the same joint at the discretion of the treating clinician, no earlier than 12 weeks after completion of the initial course, with a maximum cumulative dose of 6 Gy to the treated joint.
This registry is observational, and no experimental intervention is administered. The exposure of interest is the receipt of LDRT for osteoarthritis within routine clinical practice.
Intervention code [1] 334399 0
Not applicable
Description of the comparator or control
This study is a single-arm, observational clinical registry and does not include a comparator or control group. All participants receive low-dose radiotherapy (LDRT) as part of standard clinical care.
Control group
Uncontrolled

Outcomes
Primary outcome [1] 345775 0
Proportion of treated joints classified as Responder at 6 months following initial LDRT, as defined by the iROAR three-tier response classification below.
Timepoint [1] 345775 0
6 months following LDRT
Secondary outcome [1] 463264 0
Proportion of treated joints classified as Responder, Partial Responder, or Non-Responder. This will be assessed as a composite outcome
Timepoint [1] 463264 0
Assessed at 3, 12, 18, and 24 months post-initial LDRT
Secondary outcome [2] 463265 0
Change in pain intensity from baseline
Timepoint [2] 463265 0
Assessed at 3, 6, 12, 18, and 24 months post-initial LDRT
Secondary outcome [3] 463266 0
Change in patient global assessment from baseline
Timepoint [3] 463266 0
Assessed at 3, 6, 12, 18, and 24 months post-initial LDRT
Secondary outcome [4] 463269 0
Incidence of retreatment and subsequent clinical response. This will be assessed as a composite outcome.
Timepoint [4] 463269 0
Assessed during follow-up up to 24 months post-initial LDRT.
Secondary outcome [5] 463270 0
Incidence of unplanned joint surgery
Timepoint [5] 463270 0
Assessed during follow-up up to 24 months post-initial LDRT
Secondary outcome [6] 463271 0
Cumulative incidence of adverse events (AEs)
Timepoint [6] 463271 0
Assessed continuously from consent to 24 months post-treatment
Secondary outcome [7] 463272 0
Health resource utilisation (analgesic use, hospitalisations, radiotherapy costs). This will be assessed as a composite outcome.
Timepoint [7] 463272 0
Assessed over 24 months follow-up period
Secondary outcome [8] 463273 0
Change in health-related quality of life (HRQoL)
Timepoint [8] 463273 0
Assessed at baseline, 3, 6, 12, 18, and 24 months post-initial LDRT.

Eligibility
Key inclusion criteria
Key Inclusion Criteria


Adults aged 18 years and over.


Participants with a pre-existing diagnosis of osteoarthritis (OA).


Participants presenting to a participating centre to receive low-dose radiotherapy (LDRT) for symptomatic OA and deemed suitable for treatment by the treating Radiation Oncologist.


Evidence of OA affecting at least one joint (e.g., shoulder, hip, hand, wrist, elbow, knee, ankle, or foot), consistent with standard clinical assessment.


Able and willing to provide written informed consent to participate in the registry.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
Key Exclusion Criteria


Participants not eligible to receive low-dose radiotherapy (LDRT) for osteoarthritis, as determined by the treating Radiation Oncologist.


Severe osteoarthritis (Kellgren–Lawrence grade 4).


Previous radiotherapy to the affected joint.


Planned or scheduled joint surgery for the affected joint within the study follow-up period (2 years).


History of prior surgery on the affected joint.


Current participation in another clinical trial for treatment of osteoarthritis.


Autoimmune conditions affecting the joint (e.g., rheumatoid arthritis, lupus).


Fibromyalgia diagnosis.

Study design
Purpose
Natural history
Duration
Longitudinal
Selection
Convenience sample
Timing
Statistical methods / analysis

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
SA
Recruitment hospital [1] 29645 0
Icon Cancer Centre Windsor Gardens - Windsor Gardens
Recruitment postcode(s) [1] 45990 0
5087 - Windsor Gardens

Funding & Sponsors
Funding source category [1] 322149 0
Charities/Societies/Foundations
Name [1] 322149 0
Icon Cancer Foundation
Country [1] 322149 0
Australia
Primary sponsor type
Commercial sector/Industry
Name
Integrated Clinical Oncology Network (ICON) Pty Ltd
Address
Country
Australia
Secondary sponsor category [1] 325043 0
None
Name [1] 325043 0
Address [1] 325043 0
Country [1] 325043 0

Ethics approval
Ethics application status
Submitted, not yet approved
Ethics committee name [1] 320678 0
St Vincent's Hospital Melbourne Human Research Ethics Committee
Ethics committee address [1] 320678 0
Ethics committee country [1] 320678 0
Australia
Date submitted for ethics approval [1] 320678 0
13/05/2026
Approval date [1] 320678 0
Ethics approval number [1] 320678 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 151258 0
A/Prof Peter Gorayski
Address 151258 0
Icon Cancer Centre Windsor Gardens 480 North East Road, Windsor Gardens SA 5087
Country 151258 0
Australia
Phone 151258 0
+61 8164 3600
Fax 151258 0
Email 151258 0
Contact person for public queries
Name 151259 0
Bianca Karle
Address 151259 0
Icon group (research) Level 1/22 Cordelia St, South Brisbane QLD 4101
Country 151259 0
Australia
Phone 151259 0
+61 07 3737 4500
Fax 151259 0
Email 151259 0
Contact person for scientific queries
Name 151260 0
Peter Gorayski
Address 151260 0
Icon Cancer Centre Windsor Gardens 480 North East Road, Windsor Gardens SA 5087
Country 151260 0
Australia
Phone 151260 0
+61 0881643600
Fax 151260 0
Email 151260 0

Data sharing statement
Will the study consider sharing individual participant data?
No
No IPD sharing reason/comment: Data will be aggregated for analysis



What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.